SCOTUS gives Gilenya generics the green light in fresh blow to Novartis
The move is latest setback for the patentee in its dramatic written description dispute
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.